Hikma Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio
Hikma Pharmaceuticals (Berkeley Heights, NJ): 57 reconciled FDA prescription therapies, $1.42B 2024 CMS Part D & Medicaid spend, and 56 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Berkeley Heights, NJ |
| Reconciled FDA Portfolio Therapies | 57 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2033-01-01 |
| 2024 CMS Total Public Spend | $1.42B |
| 2024 Medicare Part D Spend | $712.0M |
| 2024 Medicaid Spend | $704.1M |
| California HCAI SB 17 Filings | 56 WAC filings (max 2368.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Hikma Pharmaceuticals across sibling Meru public-data platforms.